Third, the biomarker criteria used for entry (BNP ≥ 40 pg/ml or NT-proBNP ≥ 400 pg/ml) represent relatively low thresholds for patients on dialysis and may have allowed inclusion of participants with less advanced disease, unlike conventional heart failure trials that typically include patients with more advanced symptoms. Here, NPPB is linked to heart failure.